News Conference News ACC 2026 PCSK9 Inhibitor Very Effective in High-risk Patients Without ASCVD: VESALIUS-CV Michael O'Riordan March 29, 2026
Presentation ACC 2026 Intensive LDL cholesterol targeting in atherosclerotic cardiovascular disease: The Ez-PAVE randomized clinical trial Presenter: Byeong-Keuk Kim March 28, 2026
News Daily News Ultraprocessed Food Again Linked to Higher CVD Risk: MESA Michael O'Riordan March 17, 2026
News Daily News Healthy Lifestyle Plus GLP-1s Yields Bigger CV Reduction Than Drugs Alone Michael O'Riordan March 03, 2026
News Daily News AHA Forecast: CV Risk Factors in Women, Girls Headed in Wrong Direction L.A. McKeown March 03, 2026
News Daily News Oral GLP-1s Provide Benefit in HF Patients: SOUL Subanalysis L.A. McKeown February 06, 2026
News Daily News Nearly 150 Million US Adults Eligible for CKM Syndrome Meds Caitlin E. Cox February 02, 2026
News Daily News JACC Debuts Data Digest on CV Health in the United States Caitlin E. Cox January 12, 2026
News Daily News Statins Work for Primary Prevention Even in Low-risk Patients With Type 2 Diabetes Todd Neale January 05, 2026
News Daily News SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide Michael O'Riordan December 18, 2025
News Conference News AHA 2025 Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV Michael O'Riordan November 08, 2025
News Daily News Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients Caitlin E. Cox October 22, 2025
News Daily News Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks Michael O'Riordan August 01, 2025
News Daily News Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT Michael O'Riordan July 31, 2025
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for July 2025 Caitlin E. Cox July 31, 2025